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Antiprothrombin antibodies detection comprises two different ELISAs: prothrombin coated on 
irradiated plates (aPT) or phosphatidylserine/prothrombin (aPS/PT) as the antigen. While several 
commercial kits are available for the detection of aPT, aPS/PT are usually detected by in-house 
assays. Recently, a new commercially available kit was launched and, therefore, we decided to test 
its efficiency by comparing it to our in-house assay. 
Methods 
aPS/PT were tested by our in-house assay (aPS/PTih) in 75 SLE patients, using Immulon 1 plates 
coated with phosphatidylserine, purified human prothrombin and 1%BSA-TBS-CaCl as blocking 
and diluents. Data from this assay were compared to those obtained by the QUANTA Lite™ 
aPS/PT screen, IgG and IgM Elisa (INOVA Diagnostics, Inc, San Diego, USA) commercial kits 
(aPS/PTc). 
Results 
aPS/PT were found in 41.3% and 46.7% of SLE patients by the aPS/PT ih and the aPS/PTc, 
respectively. There was a positive correlation between IgG aPS/PT ih and aPS/PTc assays (R2 = 0. 
861 by Spearman test, p = 0.0027). Sensitivity and specificity for APS were 62.2% and 97.4% 
(AUC 0.780) for the aPS/PTih assay and 70.3% and 84.2% (AUC 0.858) for the aPS/PTC. Shorter 
running times were also seen when comparing the aPS/PTih vs. aPS/PTc (7 hours vs. 3 hours, 
respectively). 
Conclusion 
The aPS/PTC is a reproducible and accurate test for the detection of aPS/PT, bringing also the 
advantage of shorter running times. 
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In clinical practice, anticardiolipin antibody (aCL), antiβ2glycoprotein I (aβ2GPI), detected by 
enzyme-linked immunosorbent assay (ELISA) and the lupus anticoagulant (LA) detected by 
clotting assays have been the tests of choice for the diagnosis of the antiphospholipid syndrome 
(APS). However, antiphospholipid antibodies (aPL) are a heterogeneous family of 
immunoglobulins that do not bind to phospholipids but to plasma proteins with affinity for anionic 
surfaces (i.e. phospholipids). Evidence gathered through years of work suggests that aPL are 
directed against specific phospholipid binding plasma proteins such as β2 glycoprotein I and 
prothrombin, among others [1] and [2]. Antibodies to prothrombin are frequently found in patients 
with systemic lupus erythematosus (SLE) and have been associated with thrombosis and recurrent 
pregnancy loss [3] and [4]. 
Antiprothrombin antibodies are commonly detected by ELISA, using irradiated plates 
(aPT) [3] and [5] or in complex with phosphatidylserine (aPS/PT) [3], [6] and [7]. The mode of 
presentation of prothrombin in solid phase seems to influence its recognition by antiprothrombin 
antibodies. In fact, antiprothrombin antibodies cannot bind when prothrombin is immobilised onto 
non-irradiated plates [5] and [6], but do so if prothrombin is immobilised on a suitable anionic 
surface, adsorbed on gamma irradiated plates or exposed to immobilised anionic phospholipids. 
While several commercial kits are available for the detection of aPT, aPS/PT are usually detected 
by in-house assays. 
Recently, a new aPS/PT commercially available kit was launched and, therefore, we decided to test 
its efficiency and analyse its clinical performance by comparing the results to our in-house assay in 
a cohort of patients with SLE. 
 
Patients and Methods 
This study included 75 consecutive patients, all fulfilling the 1982 criteria for SLE [8]. Of these, 37 
patients fulfilled criteria for definite APS [9] and [10]. Patients group comprised 70 female and 5 
male with a mean age of 43.7 ± 11.9 years and mean disease duration of 13.1 ± 9.1 years. 
Overall, 46 patients had a history of thrombosis, including 18 arterial, 15 venous and 13 both 
arterial and venous thrombosis. Out of 49 women who had ever been pregnant, 16 had a history of 
miscarriages and 20 a history of fetal death. Demographics are summarised in Table 1. 
Ethical approval was obtained from the Guy’s and St Thomas’ Ethics committee and all patients 
involved in this study gave their written consent. 
Blood Collection 
Blood was collected by venopuncture from the antecubital vein into pre-cooled tubes containing 
0.105 M sodium citrate and in non-anticoagulated tubes (Hemogard® 9NC and Hemogard® Z, 
respectively, Becton Dickinson, Rutherford, USA). Platelet free plasma was obtained by 
centrifugation at 2500 g for 20 minutes and filtration using a 0.2 μm surfactant free cellulose acetate 
membrane (Nalgene, Rochester, NY, USA). Plasma was stored at − 80 °C until used. For sera 
preparation, blood was allowed to clot at room temperature and then centrifuged at 2000 g for 
20 minutes. Sera were subsequently aliquoted and stored frozen at − 80 °C until use. 
Antibodies to Phosphatidylserine-Prothrombin 
Antibodies were tested by an in-house assay (aPS/PTih) and by a commercially available kit 
(aPS/PTc). 
aPS/PTih were tested as previously reported [3]. Briefly, Microtitre ELISA plates (Immulon 1, 
Dynatech, Virginia, USA) were coated with 30 μl of 50 μg/ml phosphatidylserine (Sigma) in 
methanol/chloroform (4:1) overnight at 4 °C. After blocking with 1% bovine serum albumine in 
Tris buffer saline and 5 mM CaCl2 (1%BSA-TBS-CaCl2), plates were washed twice with TBS- 
5 mM CaCl2–0.005% Tween and 10 μg/ml purified human prothrombin (Enzyme Research 
Laboratories Inc, Swansea, UK) were added and incubated at 37 °C. After one hour, serum samples 
diluted 1:100 in 1%BSA-TBS-CaCl2 were added in duplicate. Plates were incubated for one hour, 
followed by alkaline phosphatase-conjugated goat anti-human IgG or IgM (Sigma) and substrate. 
aPS-PTih titre of each samples was derived from a curve constructed by serial dilutions of a high 
binding sera used as standard. The cut off value was established at 2U for aPS-PTih IgG and 11U for 
aPS-PTih IgM, determined by the mean plus 3 standard deviations of 100 healthy controls. To avoid 
interference of anti-phosphatidylserine antibodies, all samples were tested in parallel in wells 
containing only phosphatidylserine. 
aPS/PTc were tested by using the QUANTA Lite™ aPS/PT screen, IgG and IgM Elisa (INOVA 
Diagnostics, Inc, San Diego, USA), according to manufacturer’s recommendations.  
Other aPL 
The aCL and anti-β2GPI ELISAs were performed according to the current 
recommendations [2] and [11]. Anti-β2GPI were detected by ELISA as described previously [12], 
using irradiated microtitre plates (Nunc Maxisorp, Denmark). 
Plasma samples were tested for the presence of LA according to the recommended criteria from the 
ISTH Subcommittee on Lupus Anticoagulant-Phospholipid-dependent antibodies [13] and [14]. All 
samples were tested by the activated partial thromboplastin time (aPTT - IL test™ APTT-SP, 
Instrumentation Laboratory, Italy) and the dilute Russell viper venom time (dRVVT- Diagen 
Russell’s viper venom, Diagnostic Reagents Ltd, Oxon, UK) coagulation test. Both screen and 
confirm steps were performed. 
Statistical Analysis 
Statistical analysis was performed using SPSS 19.0 program (Microsoft software). Comparisons 
between patients and controls and patients groups were expressed as odds ratio with its 95% 
confidence interval (OR [95%CI]), where a lower limit > 1.0 was considered significant. The 
degree of linear association between aPS/PTih and aPS/PTcwas quantified by the Spearman 
correlation method. Differences between means were analysed by the Mann–Whitney test. All p 
values were determined by Fisher’s exact test. A p value of < 0.05 was considered statistically 
significant. 
Results 
Overall, aPS/PT were found in 41.3% and 46.7% of SLE patients by the aPS/PTih and aPS/PTc, 
respectively. Total running time for the aPS/PTih was 7 hours vs. 3 hours for the aPS/PTc. Data on 
prevalence of aPL, including aPS/PT are depicted in Table 2. 
Overall results were in accord in 65/75 samples (86.6%) for IgG and/or IgM, with 63/75 (84%) for 
IgG and 61/75 (81.3%) for IgM, respectively. All data are summarised in Table 3. IgG and/or IgM 
aPS/PTih and aPS/PTc were found simultaneously in 28/38 (73.7%) patients found to be positive 
with any aPS/PT test. IgG were concomitantly found in 23/35 patients who were positive in any 
IgG aPS/PT test (65.7%), IgM aPS/PT in 14/28 (50%). All data are shown in Fig. 1. 
There was a positive correlation between IgG aPS/PTih and aPS/PTc by Spearman test (R2 = 0.861, 
p = 0.0027) (Fig. 2A). Although less strong than that found for the IgG isotype, a positive 
correlation was also seen between IgM aPS/PTih and aPS/PTc (R2 = 0.54, p = 0.003) (Fig. 2.B). 
Sensitivity and specificity for APS were 62.2% and 97.4% (AUC 0.780) for the aPS/PTih and 
70.3% and 84.2% (AUC 0.858) for the aPS/PTc, respectively. The presence of aPS/PT by both, 
aPS/PTih and aPS/PTc was associated with thrombosis. All data are summarised in Table 4. 
 
Discussion 
In this study we aimed to test the efficiency and analyse the clinical performance of a new 
commercially available kit for aPS/PT testing by comparing the results to our in-house assay. 
aPS/PT have been previously reported to be associated with thrombosis and recurrent pregnancy 
loss [3], [6] and [7]. Recent data from our group [15] confirms that their inclusion in the panel of 
antibodies tested for APS can result in a higher diagnostic power and in helping to stratify the 
thrombotic risk in patients with SLE. 
To the best our knowledge, no commercial ELISA test has been previously evaluated and this is the 
first study testing the clinical accuracy of a commercial kit for aPS/PT. As these antibodies are not 
part of the routinely tested panel of aPL and no consensual standardized method exists for their 
detection, the validation of an available commercial kit is largely desirable. 
In this study, the comparison of the overall diagnostic performance by AUCs, a conventional 
method [16], confirmed that both the assays, aPS/PTih and aPS/PTc, reached a good level of 
accuracy (AUC 0.780 and 0.858, respectively), and were able to identify patients with APS, both in 
terms of thrombosis and/or pregnancy loss. 
Although sensitivity and specificity were similar between the two assays, the aPS/PTcassays 
showed a slightly higher number of positive results, with the consequential higher sensitivity to the 
expense of the specificity. 
We report that the aPS/PTc ELISA test is also a rapid and simple method. The mean-time of the 
analysis is reduced with the commercial method which includes fewer time-consuming procedures 
(data not shown). This results in the reduction of potential analytical variables thanks to a simpler 
protocol and a shorter testing time. In addition, it offers a valid diagnostic tool for APS diagnosis 
mainly for those centres where in-house assays are not available or affordable. In addition to these 
technical advantages, adopting a commercial kit may help in guaranteeing the comparability of 
results between laboratories, although a closer collaboration with kit companies is necessary for the 
success of this sort of initiative. 
While the need for routine testing for aPS/PT is still under debate, there is overwhelming clinical 
evidence that these antibodies are associated with thrombosis and pregnancy loss in patients with 
APS and that their presence increases the risk of developing such an event [17], [18] and [19]. 
Therefore, the technical assessment of available methods for the detection is timely. 
In conclusion, the results of this study demonstrated that the analysed commercially available 
ELISA kit is a satisfactory and time-effective method for the testing of aPS/PT, at least when 
compared to our in-house assay. 
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Table 1. Demographic characteristics. 
 N = 75 (%) 
Female (%) 70 (93.3) 
Mean age ± SD 43.7 ± 11.9 
Mean disease duration ± SD 13.1 ± 9.1 
APS* 37 (49.3) 
Thrombosis 46 (61.3) 
 -Arterial thrombosis † 31 (41.3) 
 -Venous thrombosis † 28 (37.3) 
Pregnancy loss ‡ 22 (44.9) 
 - Miscarriages (≥ 1) 16 (32.7) 
 - Miscarriages (≥ 3) 6 (12.2) 
 - Fetal death 20 (40.8) 
SLE: systemic lupus erythematosus, APS: antiphospholipid syndrome, *some patients fulfil criteria for both SLE and 
APS, † 13 patients from each group have both arterial and venous thrombosis, ‡ pregnancy loss defined by 
criteria [9] and [10]. All pregnancy data percentages calculated over the total number of female who had ever been 
pregnant (n = 49). 
 
 
Table 2. aPL distribution in SLE cohort. 
aPL n = 75 (%) 
aCL IgG/IgM 31 (41.3) 
 - aCL IgG 30 (40) 
 - aCL IgM 15 (20) 
Anti-β2GPI IgG/IgM 27 (36) 
 - Anti-β2GPI IgG 25 (33.3) 
 - Anti-β2GPI IgM 6 (8) 
LA 25 (30.3) 
aPS/PTih IgG/IgM 31 (41.3) 
 - aPS/PTih IgG 25 (33.4) 
 - aPS/PTih IgM 19 (25.3) 
aPS/PTc IgG/IgM 35 (46.7) 
 - aPS/PTc IgG 33 (44) 
 - aPS/PTc IgM 23 (30.7) 
 










Table 3. Level of agreement/disagreement between commercial and in-house assays. 
 
aPS/PTih 
aPS/PTc N = 75 (%) 
IgG and/or IgM*   65 (86.6) 
+ + 28 (37.3) 
- - 37 (49.3) 
  10 (13.3) 
- + 7 (9.3) 
+ - 3 (4) 
IgG   63 (84) 
+ + 23 (30.6) 
- - 40 (53.4) 
  12 (16) 
- + 10 (13.3) 
+ - 2 (2.7) 
IgM   61 (81.3) 
+ + 14 (18.6) 
- - 47 (62.7) 
  14 (18.6) 
- + 9 (12) 
+ - 5 (6.6) 







Fig. 1.  Distribution of aPS/PT positivity between assays. 
 
 





Table 4. aPS/PT in thrombosis and pregnancy loss (PL). 
 
*PL: pregnancy loss. All pregnancy data are calculated over the total number of female who had ever been pregnant (n 
= 49). 
